By Gina Shaw
On Oct. 12, 2022, the FDA reported a shortage of the immediate-release formulation of amphetamine mixed salts (Adderall/Adderall IR, Teva) on its drug shortage website, confirming a rash of reports that began over the summer.
Other manufacturers also make the stimulant, which is approved to treat attention-deficit/hyperactivity disorder (ADHD) and narcolepsy, but Teva is by far the largest supplier of both branded and generic versions.